Clinical-stage Opportunity OnKure Therapeutics, a clinical-stage biopharmaceutical company focusing on precision PI3Kα inhibitors, presents opportunities to engage for collaboration, CRO partnerships, or strategic funding discussions around early-phase trials and companion diagnostics.

Lead ProgramIQ OKI-219 and the PI3Kα[H1047R] mutant-selective program offer a potential entry point for partnered development, licensing discussions, or joint ventures with firms seeking mutant-selective oncology assets and safety-efficacy differentiation.

Investor & Conference Target Active participation in major healthcare investor events (e.g., Morgan Stanley Global Healthcare Conference) signals readiness for investor-focused BD conversations, time-sensitive outreach for partnerships, and visibility to potential strategic investors or acquirers.

Growth Readiness With revenue in the low to mid single digits and substantial funding, OnKure is positioned to evaluate collaboration models such as co-development, milestone-based partnerships, or grant-supported studies to advance its lead programs.

Digital Footprint Utilize the company’s modern tools (DocuSign, Exchange Online Protection, GoDaddy) to streamline outreach, contract workflows, and secure communication, enabling faster deal negotiations and protected data exchange with potential partners.